,38 More recently, SGLT2 inhibitors have been associated with a mild increase in serum Mg2+ levels (0.06–0.3 mM) in patients with diabetes with or without hypomagnesemia at baseline.39, 40, 41 The mild increase in serum magnesium level is, however, significant because of the inherent difficulty to raise serum magnesium by oral supplementation in patients with a renal magnesium leak. Here, SLC5A2 is linked to familial primary hypomagnesemia.